Radiopharm Theranostics looks set to fill its coffers with a healthy $18 million following a strategic equity investment and asset transfer deal with leading United States-based radiopharmaceutical company Lantheus Holdings.
Lantheus has agreed to make the initial strategic equity investment of $7.5 million in Radiopharm at an offer price of 0.5c per share – a whopping 47 per cent premium to…
